Thymosin beta-4 (Tβ4), widely supplied under the research alias TB-500, is a 43-amino-acid actin-sequestering peptide originally isolated from calf thymus and now recognized as a broadly distributed regulator of the cellular actin cytoskeleton. Beyond its housekeeping role of buffering the monomeric G-actin pool, the peptide has been studied as an extracellular mediator of cell migration, angiogenesis, and tissue repair across dermal, corneal, cardiac, vascular, and neurological injury models. It has also advanced into early-phase human clinical pharmacology in defined formulations such as the ophthalmic solution RGN-259. This overview compiles published scientific literature on the molecule for laboratory and research reference only.

Background & Discovery

Thymosin beta-4 (Tβ4) is a small, ubiquitous 43-amino-acid polypeptide that was originally isolated from calf thymus tissue during efforts to characterize thymic hormones, and it was later recognized to be the principal G-actin (monomeric actin) sequestering molecule in most eukaryotic cells. Despite the "thymosin" name, the peptide is not restricted to the thymus: it is broadly distributed across tissues and body fluids and is among the most abundant intracellular peptides in many cell types. In the research-chemical and peptide-supply market, the designation "TB-500" is commonly applied to synthetic full-length thymosin beta-4, although some vendors and reports have used "TB-500" more narrowly to describe the N-terminal actin-binding fragment (a short peptide containing the LKKTET motif). Because of this nomenclature ambiguity, the literature grounding for "TB-500" is drawn from the extensive peer-reviewed body of work on thymosin beta-4 itself.

Interest in Tβ4 as a research subject grew when investigators observed that, beyond its housekeeping role in buffering the actin monomer pool, the peptide "moonlights" as an extracellular mediator of cell migration, angiogenesis, and tissue repair. Reviews by Goldstein, Hannappel, and Kleinman framed Tβ4 as an actin-sequestering protein with a second, injury-repair vocation, and this dual identity has driven study of the peptide across dermal, corneal, cardiac, vascular, and neurological injury models.

Within the research literature, Tβ4 is categorized as a regenerative/repair-associated peptide and as a cytoskeletal regulatory protein. It has advanced into early-phase human clinical pharmacology in specific formulations (for example, the ophthalmic solution RGN-259 and intravenous formulations evaluated for pharmacokinetics and tolerability), which places it in the relatively small group of research peptides for which both extensive preclinical data and published human pharmacology exist. All content here is compiled for laboratory and research reference only.

Chemical Identity

Structure & Physicochemical Properties

Thymosin beta-4 is a single-chain, 43-residue acidic peptide with an average molecular weight of approximately 4963 g/mol and the molecular formula C212H350N56O78S. Its sequence is N-terminally acetylated (acetyl-serine) and contains a single methionine residue, which accounts for the lone sulfur atom in the formula; notably, it contains no cysteine and therefore forms no intramolecular disulfide bonds. The peptide is rich in charged residues (multiple lysine and glutamate/aspartate residues), giving it high aqueous solubility, and it is classified as an intrinsically disordered (natively unstructured) peptide that adopts limited secondary structure in dilute aqueous solution but can gain helical character upon binding partners such as G-actin. The conserved central LKKTET motif constitutes the core actin-binding site.

As a small, highly hydrophilic and heat-stable peptide, Tβ4 is typically supplied as a white to off-white lyophilized powder that is readily soluble in water and aqueous buffers such as phosphate-buffered saline. The absence of cysteine removes disulfide-related oxidation concerns, though the single methionine is susceptible to oxidation, and the acetylated N-terminus and free C-terminal carboxyl are relevant to identity confirmation. Reference databases (PubChem CID 16132341; CAS 77591-33-4) provide the authoritative identity values used to verify supplied material.

Mechanism of Action — as described in the literature

The best-characterized activity of thymosin beta-4 is sequestration of monomeric G-actin. Tβ4 binds G-actin in an approximately 1:1 complex through its central LKKTET motif, holding actin monomers in an unpolymerized, assembly-incompetent state. By maintaining a reservoir of sequestered G-actin, the peptide buffers the dynamic equilibrium between monomeric G-actin and filamentous F-actin, thereby influencing cytoskeletal remodeling that underlies cell shape change, adhesion turnover, and directional migration. In cell-biology research Tβ4 is treated as the major actin-sequestering peptide of eukaryotic cells, and this cytoskeletal role is considered foundational to its downstream effects on motile cell populations.

Beyond intracellular actin regulation, the peer-reviewed literature describes Tβ4 as a secreted, extracellular mediator that promotes angiogenesis and cell migration. Work localizing the angiogenic activity to the actin-binding region showed that the seven-amino-acid actin-binding motif is both necessary and sufficient to reproduce Tβ4’s pro-angiogenic behavior in endothelial migration and aortic-ring sprouting assays, indicating mechanistic overlap between the actin-binding site and the peptide’s repair-associated signaling. Reported extracellular effects include stimulation of endothelial cell migration, adhesion, and tubule formation, as well as keratinocyte and corneal epithelial migration relevant to re-epithelialization.

In cardiac systems, Tβ4 has been reported to engage a distinct survival-signaling axis. Studies in embryonic and postnatal cardiomyocytes described formation of a functional complex among Tβ4, the adaptor protein PINCH, and integrin-linked kinase (ILK), leading to activation of the survival kinase Akt (protein kinase B). This pathway was associated with enhanced cardiomyocyte survival and migration and with improved cardiac function following experimental coronary artery injury, positioning ILK/Akt signaling as a candidate mediator of the peptide’s cytoprotective effects in myocardium.

The literature also attributes anti-inflammatory and cytoprotective properties to Tβ4. In ocular surface injury models, Tβ4 reduced inflammatory cell infiltration and downregulated pro-inflammatory signaling (including effects on NF-κB-associated pathways), while promoting epithelial repair. Related reports describe antioxidant and anti-apoptotic activity in stressed cells. A biologically important cleavage product, the N-terminal tetrapeptide Ac-SDKP (acetyl-Ser-Asp-Lys-Pro), is generated from Tβ4 and carries its own documented anti-fibrotic, anti-inflammatory, and hematopoietic-modulating activities, adding a metabolite-level dimension to the parent peptide’s actions.

In regenerative and neurological contexts, Tβ4 has been reported to mobilize progenitor and stem cell populations, interact with extracellular matrix components (including effects on laminin and matrix-remodeling enzymes), and support processes such as hair follicle development. In central nervous system injury models, investigators have described promotion of angiogenesis, neurogenesis, oligodendrogenesis, and axonal/vascular remodeling as candidate mechanisms underlying improved functional recovery. Collectively, these mechanisms are described in the literature as a combination of a core actin-sequestering function and a broader set of "moonlighting" signaling activities in migration, survival, angiogenesis, inflammation, and matrix remodeling.

Key Published Findings

• Dermal wound healing (rodent). In full-thickness rat and mouse wound models, topically or intraperitoneally applied thymosin beta-4 increased re-epithelialization by approximately 42% over saline controls at day 4 and by as much as 61% at day 7, with greater wound contraction, increased collagen deposition and angiogenesis, and stimulation of keratinocyte migration at low peptide concentrations.[2]
• Angiogenesis mechanism (in vitro/ex vivo). Researchers mapped Tβ4’s angiogenic activity to its seven-amino-acid actin-binding motif, reporting that this short motif alone reproduced angiogenic behavior comparable to the full peptide in human endothelial cell migration and chick aortic-ring sprouting assays, while fragments lacking part of the motif were inactive.[3]
• Cardiac cell survival and repair (mouse). In embryonic and postnatal cardiac cells, Tβ4 formed a functional complex with PINCH and integrin-linked kinase (ILK), activating Akt; in mice with coronary artery ligation, treatment was associated with increased ILK/Akt activity, improved early cardiomyocyte survival, and enhanced cardiac function.[4]
• Corneal repair and inflammation (mouse alkali injury). Following corneal alkali injury in mice, Tβ4 promoted corneal re-epithelialization and decreased inflammatory (polymorphonuclear) cell infiltration, characterizing the peptide as a corneal wound-healing and anti-inflammatory agent in vivo.[6]
• Human clinical pharmacology (dry eye, phase 2). In a randomized, double-masked, placebo-controlled phase 2 trial, an ophthalmic solution of thymosin beta-4 (RGN-259, 0.1%) was reported to improve signs and symptoms of severe dry eye relative to vehicle control.[7]
• CNS injury / stroke recovery (rat). When administered beginning 24 hours after embolic middle cerebral artery occlusion, Tβ4 was reported to improve functional neurological outcome in rats, consistent with a neurorestorative profile in the sub-acute phase.[8]
• Human safety and pharmacokinetics (phase 1 IV). A randomized, placebo-controlled single- and multiple-ascending-dose study of intravenous Tβ4 in healthy volunteers (dose cohorts spanning 42 to 1260 mg) reported infrequent, mild-to-moderate adverse events with no dose-limiting toxicities and an approximately dose-proportional pharmacokinetic profile.[9]

Research Applications

• Investigated in rodent dermal and full-thickness excisional wound-healing models for re-epithelialization, contraction, and angiogenesis
• Studied in corneal epithelial wound-healing and ocular-surface inflammation models, including alkali-injury and dry-eye systems
• Examined in cardiac ischemia and myocardial infarction models for cardiomyocyte survival and functional cardiac repair
• Investigated as a probe of angiogenesis, characterizing endothelial cell migration, adhesion, and tubule formation in vitro and ex vivo
• Studied in central nervous system injury models (embolic stroke and traumatic brain injury) for neurorestoration, angiogenesis, and neurogenesis
• Used as a tool compound in cell biology to study G-actin sequestration and actin cytoskeletal dynamics
• Examined in anti-inflammatory and anti-fibrotic research, including studies of its N-terminal cleavage fragment Ac-SDKP
• Investigated in hair follicle development and stem/progenitor cell migration and mobilization studies
• Characterized in early-phase human clinical pharmacology, including ophthalmic-solution efficacy studies and intravenous pharmacokinetic/safety evaluation

Related & Comparator Compounds

Within the beta-thymosin family, Tβ4 is the most studied member and is often compared with thymosin beta-10 (Tβ10), a closely related actin-sequestering peptide with overlapping but distinct expression patterns. A mechanistically important comparator is Ac-SDKP, the N-terminal tetrapeptide generated by proteolytic processing of Tβ4, which the literature characterizes as an anti-fibrotic and anti-inflammatory metabolite in its own right rather than a mere fragment. The full-length peptide is also distinguished from short synthetic actin-binding-domain constructs: because "TB-500" is used inconsistently in the trade to denote either full-length Tβ4 or an LKKTET-containing fragment, researchers are advised to confirm which species a given material actually contains. Clinical-formulation names such as RGN-259 (ophthalmic Tβ4) and the INN "timbetasin" refer to defined preparations of the same molecule. More broadly, Tβ4 is frequently grouped in "tissue-repair peptide" research alongside unrelated compounds such as BPC-157, although these differ entirely in sequence and mechanism; and its actin-regulatory role sits alongside, but is mechanistically distinct from, other actin-binding proteins such as profilin and gelsolin.

Handling, Reconstitution & Storage

In research settings, thymosin beta-4 is typically supplied as a lyophilized (freeze-dried) white to off-white powder and is described as readily soluble in water; reconstitution is commonly performed with sterile or bacteriostatic water, or with an aqueous buffer such as phosphate-buffered saline, to prepare stock solutions for in vitro or preclinical work. Published handling practice for research peptides of this type calls for storing the lyophilized powder desiccated at -20°C (or colder) for long-term stability, keeping reconstituted solutions refrigerated at 2–8°C for short-term use and frozen aliquots at -20°C or below for longer storage, and avoiding repeated freeze-thaw cycles that can promote degradation or aggregation. Because the peptide is hygroscopic and contains an oxidation-sensitive methionine, brief equilibration of cold vials to room temperature before opening and protection from prolonged light and oxidative exposure are commonly recommended. All such handling is described strictly in a laboratory research context and does not constitute guidance for human or veterinary administration.

Analytical & Quality Considerations

Analytical characterization of thymosin beta-4 for research use generally combines chromatographic purity assessment with orthogonal identity confirmation. Reversed-phase high-performance liquid chromatography (RP-HPLC) is the standard purity method, with research-grade material typically specified at high purity (commonly ≥98%), while mass spectrometry (ESI-MS or MALDI-TOF) confirms identity against the expected average mass of approximately 4963 Da. Amino acid analysis or sequencing can further verify composition and the N-terminal acetylation, and counterion/water-content and endotoxin testing are relevant quality parameters for a hydrophilic salt-form peptide. Third-party (independent) certificates of analysis matter because research-grade peptides can vary substantially between lots and suppliers: common quality issues include truncated or deletion sequences, incomplete acetylation, residual synthesis reagents or counterions (acetate/TFA), methionine oxidation, and aggregation, none of which are apparent from labeling alone. Independent HPLC/MS verification against authoritative reference values (PubChem CID 16132341; CAS 77591-33-4) therefore provides objective confirmation of identity and purity.

Frequently Asked Research Questions

Q. What is TB-500 and how does it relate to thymosin beta-4?
A. In research and peptide-supply usage, "TB-500" most often refers to synthetic full-length thymosin beta-4 (Tβ4), a 43-amino-acid actin-sequestering peptide, though some sources use the name for a shorter fragment containing the actin-binding motif. The peer-reviewed literature underpinning the compound is the body of work on thymosin beta-4 itself. This information is provided for laboratory research reference only.

Q. What is the actin-binding motif in thymosin beta-4?
A. The conserved central sequence LKKTET (approximately residues 17–22) is the core actin-binding motif. Research has shown this short motif is essential for both G-actin sequestration and the peptide’s angiogenic activity in endothelial migration and vessel-sprouting assays.

Q. Is thymosin beta-4 the same as Ac-SDKP?
A. No. Ac-SDKP (acetyl-Ser-Asp-Lys-Pro) is the N-terminal tetrapeptide produced by proteolytic processing of thymosin beta-4. It is a distinct, smaller molecule that the literature characterizes as having its own anti-fibrotic and anti-inflammatory activity.

Q. Has thymosin beta-4 been studied in humans?
A. Yes, in early-phase clinical pharmacology. Published studies include a randomized phase 2 trial of a thymosin beta-4 ophthalmic solution (RGN-259) in severe dry eye and a phase 1 randomized, placebo-controlled intravenous study in healthy volunteers assessing safety and pharmacokinetics. These are summarized here as scientific literature, not as health guidance.

Q. What molecular identity values distinguish authentic thymosin beta-4?
A. Authentic Tβ4 has the molecular formula C212H350N56O78S, an average mass of about 4963 g/mol, CAS 77591-33-4, and PubChem CID 16132341 (Timbetasin). It is a 43-residue, N-acetylated, cysteine-free peptide with a single methionine and no disulfide bonds.

Q. How is thymosin beta-4 handled and verified in a research laboratory?
A. It is commonly stored lyophilized and desiccated at -20°C, reconstituted in water or aqueous buffer, aliquoted, and protected from repeated freeze-thaw. Identity and purity are typically confirmed by RP-HPLC and mass spectrometry, ideally on an independent third-party certificate of analysis.

Peer-Reviewed References

1. Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005. PubMed →
2. Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK. Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology. 1999. PubMed →
3. Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB Journal. 2003. PubMed →
4. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004. PubMed →
5. Srivastava D, Saxena A, Dimaio JM, Bock-Marquette I. Thymosin beta4 is cardioprotective after myocardial infarction. Annals of the New York Academy of Sciences. 2007. PubMed →
6. Sosne G, Szliter EA, Barrett R, Kernacki KA, Kleinman H, Hazlett LD. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Experimental Eye Research. 2002. PubMed →
7. Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015. PubMed →
8. Morris DC, Chopp M, Zhang L, Lu M, Zhang ZG. Thymosin beta4 improves functional neurological outcome in a rat model of embolic stroke. Neuroscience. 2010. PubMed →
9. Ruff D, Crockford D, Girardi G, Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Annals of the New York Academy of Sciences. 2010. PubMed →
10. Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Annals of the New York Academy of Sciences. 2010. PubMed →
11. Dubé KN, Smart N. Thymosin β4 and the vasculature: multiple roles in development, repair and protection against disease. Expert Opinion on Biological Therapy. 2018. PubMed →

For laboratory and research use only. Not for human or veterinary use, diagnosis, or treatment. This overview summarizes published scientific literature for informational and educational purposes and is not medical advice; no claims are made regarding safety or efficacy in humans.

← Back to the Research Library · View the BPC-157 / TB-500 bundle → · COA & Testing